Clinical global response: significant response or improvement in global status (CGI‐S, high = worse) ‐ short term (4 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes clinical global response: significant response or improvement in… compared with placebo (very low certainty).
1 finding from 1 review
QoL · adults with schizophrenia
1 finding from 1 review
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with both severe mental illness and substance misuse
1 finding from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
1 finding from 1 review
Mental state: overall mean change score (BPRS total, high = poor)* · patients with schizophrenia
1 finding from 1 review
Clinical response: mean score/change in global state: mean CGI‐S score (high = poor) Medium term (12 weeks) · schizophrenia
1 finding from 1 review
Intervention not reported
Mental state: specific ‐ negative symptoms ‐ average endpoint score (SANS, high score = poor) medium term ( · People with schizophrenia and schizophrenia‐like disorders
1 finding from 1 review
Intervention not reported
Mental state: general ‐ average endpoint score (PANSS, high score = poor) ‐ medium term, ( · People with schizophrenia and schizophrenia‐like disorders
1 finding from 1 review
Intervention not reported
Mental state: General ‐ average endpoint score (BPRS, high score = poor) ‐ medium term ( · People with schizophrenia and schizophrenia‐like disorders
1 finding from 1 review
Intervention not reported
Functioning: general ‐ average endpoint score (GAF, high score = good) medium term ( · People with schizophrenia and schizophrenia‐like disorders
1 finding from 1 review
Intervention not reported
Functioning: social ‐ average endpoint score (SDSS, high score = poor) medium term, ( · People with schizophrenia and schizophrenia‐like disorders
1 finding from 1 review
Intervention not reported
Quality of life: general ‐ average endpoint score (GWB, high score = good) ‐ short term ( · People with schizophrenia and schizophrenia‐like disorders
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Clinical response: mean score/change in global state: mean CGI score (high = poor) Short term (8 weeks) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · people with treatment‐resistant schizophrenia
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Clinical response: mean score/change in global state: mean CGI‐II Global improvement score (high = poor) Short term (6 weeks) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Clinical response: mean score/change in global state: mean CGI‐S score (high = poor) Medium term (12 weeks) · people with treatment‐resistant schizophrenia
1 finding from 1 review